## Somoled

## **B S Investor Presentation**

# <section-header><section-header><text><text>

#### Disclaimer

This document has been prepared as a summary only and does not contain all information about SomnoMed Limited's (the Company's) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company's securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by the Company. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the Shares or that there will be an increase in the value of the Shares in the future.

Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company's operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as "aim", "could", "estimate", "expect", "intend", "target", "forecast", "future", "will", "may", "potential", "should" and similar expressions are forward-looking statements.

Although the Company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward-looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company's published material. Many of these factors are beyond the control of the Company and may involve subjective judgement and assumptions as to future events, which may or may not be correct.


The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.

Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.



# <section-header>

#### H1 FY25 results snapshot




#### Positive operating cash flow \$4.1m and free cash flow \$1.3m, +\$8.7m and +\$9.3m vs pcp, respectively

Figures throughout presentation are denominated in AUD, unless otherwise stated.

<sup>1</sup> EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations <sup>2</sup> PCP = prior comparative period



#### **Building the foundations for profitable growth**



<sup>1</sup> EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations. Consistent with aspirations stated in Investor Presentation 9/4/24




USe ( 1. Financial infor
2. Operations update
3. FY25 outlook

### **Soverview – H1 FY25**

**1. Financial information** 

#### **Group revenue +19% vs pcp with significant margin improvement**




<sup>1</sup> EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations



#### **Regional highlights**

Europe \$25m H1 FY24

#### **Total regional revenue**





+16%

\$4m

H1 FY25

- Strong demand facilitated by improved turnaround times resulting in double digit growth across all regions
- North American growth from all customer segments, with new customer entry particularly buoyant
- France, Sweden and Germany accelerating European results
- Australia continues to dominate APAC, with focused commercial programs and leadership driving strong performance



#### **Profit and loss summary**

| \$m  | H1 FY25 | H1 FY24 | %     |        |
|--|---------|---------|-------|--------|
| Revenue  | 53.7    | 45.1    | 19%   | •••••• |
| Gross margin   | 33.1    | 28.1    | 18%   |        |
| Sales and marketing expenses   | (11.0)  | (13.7)  | (20%) |        |
| Administrative expenses  | (8.4)   | (8.6)   | (2%)  |        |
| Operating profit<br>(before corporate, research and business<br>development) | 13.6    | 5.8     | >100% |        |
| Corporate, research and business development expenses                        | (7.8)   | (6.8)   | 14%   |        |
| EBITDA <sup>1</sup>  | 5.8     | (1.1)   | >100% |        |
| Depreciation and amortisation  | (2.9)   | (2.9)   | 1%    |        |
| Interest   | (0.1)   | (1.5)   | (92%) | •••••• |
| Other <sup>3</sup>   | (1.3)   | (0.1)   | >100% |        |
| PBT  | 1.5     | (5.5)   | >100% |        |

#### Revenue

•

•

Double digits growth across all regions Driven by continued production turn around time improvements and robust overall demand

#### Costs

•

Disciplined cost management, with budgeted operational and personnel investments

| Interest  |  |  |  |  |
|---|--|--|--|--|
| <ul> <li>Reduced interest charges following<br/>repayment of primary debt facility in Q4 FY24<br/>prior year</li> </ul> |  |  |  |  |

#### Key metrics

| Group gross margin             | 62%   | 62%   |       |
|--------------------------------|-------|-------|-------|
| EBITDA margin                  | 11%   | (2%)  | >100% |
|                                |       |       |       |
| AASB16 lease expense           | (1.4) | (1.4) | (1%)  |
| Underlying EBITDA <sup>2</sup> | 4.4   | (2.5) | >100% |

<sup>1</sup> EBITDA excludes AASB16 leases, share/option expenses, unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations <sup>2</sup> Underlying EBITDA includes AASB16 leases, but excludes unrealised foreign exchange gain/(loss), one off restructure costs and discontinued operations <sup>3</sup> H1 FY25 other includes one off conservative provision for resolution of legacy tax matters outstanding



#### **Balance sheet summary**

| \$m                           | 31 December 2024 | 30 June 2024 |   |
|-------------------------------|------------------|--------------|---|
| Cash and cash equivalents     | 18.5             | 16.2         | <ul> <li>Cash and cash equivalents</li> <li>Increased balance sheet strength</li> </ul> |
| Trade and other receivables   | 16.2             | 12.4         |   |
| Inventories                   | 6.7              | 6.3          |   |
| Property, plant and equipment | 5.8              | 5.8          |   |
| Intangible assets             | 20.3             | 20.3         |   |
| Right of use asset            | 4.6              | 5.4          |   |
| Deferred tax assets           | 2.6              | 3.1          |   |
| Other assets                  | 0.3              | 0.3          |   |
| Total assets                  | 75.0             | 69.8         |   |
| Trade and other payables      | 15.3             | 13.3         | <ul> <li>Borrowings</li> <li>Primary debt repaid in Q4 FY24 prior</li> </ul>            |
| Borrowings                    | 1.0              | 1.0          | <ul><li>✓ year</li></ul>  |
| Provisions                    | 5.3              | 4.5          | <ul> <li>Residual debt represent European<br/>government back borrowings</li> </ul>     |
| Current tax liabilities       | 1.0              | 0.2          |   |
| Lease liabilities             | 4.9              | 5.7          |   |
| Total liabilities             | 27.5             | 24.8         |   |
| Net assets                    | 47.5             | 45.0         |   |



#### **Cash flow summary**

| <b>\$m</b>  | H1 FY25 | H1 FY24 |   |
|---|---------|---------|---|
| EBITDA <sup>1</sup>   | 5.8     | (1.1)   |   |
| Movement in working capital and other non-cash                      | (1.5)   | (1.7)   |   |
| Tax paid  | (0.3)   | (0.7)   | Interest  |
| Net finance costs paid  | (0.0)   | (1.1)   | Reduced interest charges following     repayment of primary debt facility in Q4 |
| Operating cash flow   | 4.1     | (4.6)   | FY24 prior year   |
| Payments for intangible assets                                      | (0.7)   | (1.7)   |   |
| Payments for property, plant and equipment                          | (0.6)   | (0.5)   | Investing   |
| Investing cash flow   | (1.4)   | (2.2)   | Continued investments in R&D and CPF  |
| (Payment of)/proceeds from issue of shares net of transaction costs | (0.0)   | 14.6    | manufacturing infrastructure  |
| Borrowings / (repayment of borrowings)                              | (0.1)   | (5.1)   | <ul> <li>Borrowings</li> <li>Primary debt repaid in Q4 FY24 prior</li> </ul>    |
| Payment of finance leases   | (1.4)   | (1.2)   | year  |
| Financing cash flow   | (1.5)   | 8.2     |   |
| Exchange rate adjustments   | 1.2     | (0.6)   |   |
| Net cash flow   | 2.3     | 0.9     |   |
|   |         |         |   |
| Key metrics   |         |         |   |
| Operating cash flow   | 4.1     | (4.6)   | Positive operating and free cash flow   |
| Operating cash flow less finance leases                             | 2.7     | (5.8)   | <ul> <li>+\$8.7m and +\$9.3m vs pcp, respectively</li> </ul>                    |
| Free cash flow  | 1.3     | (8.0)   |   |



<text>

## **Source Provision Provisio**

#### **Manufacturing highlights – latest results**

#### Capacity

Manufacturing capacity uplift by >40%

#### Turnaround time

Manufacturing production turnaround time reduced from >3 weeks to <10 days

#### Backlog

Manufacturing production backlog from >2 weeks to <2 days

#### Investing to make operations sustainable



#### **New leadership team members**



#### Jonathan Vowels: VP Manufacturing and Operations

- Former Operations Director SEA British American Tobacco
- Over 25 years manufacturing and supply chain experience

#### Ye-Fei Guo: Chief Financial Officer

- Former VP Finance at Brookfield, trained at PwC
- CA, over 20 years in finance, over 10 years at Brookfield, ASX and company secretarial experience



#### Janice Hiskett-Jones: Chief People Officer

- Former Interim CPO at SunRice
- Over 25 years HR experience specialising in incentives



#### **Keshan Gunasinghe: Chief Product Officer**

- Former VP R&D Kenvue and J&J Consumer Health Asia
- Over 20 years R&D experience J&J Asia

#### Mary Kennell: Global Director, Quality Assurance and Regulatory Affairs

- Former Head of Regulatory Affairs and Quality at Alcon
- Over 18 years regulatory and quality experience at medical device and pharma companies







Johnson & Johnson

#### Alcon



#### Sector, manufacturing and investment experience added to Board



- Former ResMed Chief Supply Chain Officer
- Over 25 years medical devices experience
- Led end to end supply chain, including supplier management, manufacturing, logistics, distributions, quality assurance and regulatory affairs
- Product development, project management and business development experience globally

#### **Benjamin Gisz**

- Director and member of investment team at TDM Growth Partners
- Extensive investing and financial markets experience







#### **Rest Assure<sup>®</sup> status Feb 2025**

- FDA cleared Rest Assure<sup>®</sup> as the <u>first</u> oral device with built-in compliance monitoring
- Clearance includes the oral device and software platform incl. patient app, physician platform, docking station and cloud systems

#### **Rest Assure<sup>®</sup> next steps**

- New FDA 510k submission underway for oral device efficacy for treated AHI centred on a US clinical trial
- Conducting FDA pre-submission to confirm regulatory approach
- Targeting selection of clinical trial sites by end FY25 and commencement of clinical trial in FY26



# **BORD OVERVIEW – FY25** 1. Financial information 2. Operations update 3. FY25 outlook

|                           | Original        | Upgrade<br>Nov24 | <b>Upgrade</b><br>Jan25 |
|---------------------------|-----------------|------------------|-------------------------|
| Revenue                   | c. \$100m       | <b>c. \$105m</b> | c. \$105m               |
| <b>EBITDA<sup>1</sup></b> | <b>&gt;\$5m</b> | <b>&gt;\$7m</b>  | <b>\$7-9m</b>           |
| Capex                     | <b>\$3-4m</b>   | <b>\$3-4m</b>    | <b>\$3-4m</b>           |



SomnoMed<sup>®</sup>

## Somnol/led

**For further information please contact:** 

Investor Relations: IR@somnomed.com.au